Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review

Executive Summary

Generic perphenazine is recommended as first-line treatment for schizophrenia by Consumer Reports Best Buy Drugs based on a comparison of efficacy, adverse events and cost-effectiveness of 13 antipsychotic drugs

You may also be interested in...



CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals

The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program

CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals

The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program

Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports

Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.

Related Content

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel